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considerably by  sequencing  the genomes of  tumors arising 
in inbred strains of mouse cancer models, since the coverage 
requirements for detecting somatic mutations are predicted 










(4–7).  In  our  knockin mouse model,  a  human PML-RARA 
cDNA was targeted to the 5′ untranslated region of the mouse 
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Flow chart for the identification of SNVs in the mouse 
9500 APL genome. Tier 1 contains all changes in amino 
acid coding regions of annotated exons and consensus 
splice-site regions.
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Heat map of residual 129/SvJ SNPs by chromosomal location. A heat map was generated to show the number of SvJ/129 SNPs present in 
the tumor 9500 genome per 1-Mb window divided by the number total SvJ/129 SNPs present in the same 1-Mb window, aligned to the mouse 
chromosome ideogram. The location of cathepsin G (Ctsg) is highlighted by an arrow. The mouse 9500 breeding strategy placed selective pres-
sure to retain the genetically modified Ctsg locus on chromosome 14 (the PML-RARA cDNA was knocked into the 5′ untranslated region of the 
Ctsg gene). The experimentally derived heat map shows a skewing of retained 129/SvJ SNPs surrounding the Ctsg locus, as expected, with a 
random distribution of 129/SvJ SNPs throughout the remaining chromosomes. Min., minimum.
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Figure 3
Functional validation of the recurrent Jak1 mutation identified in the sequenced mouse APL genome. (A) The mouse Jak1 V657F (mJAK1) 
mutation is orthologous to the human JAK1 V658F (hJAK1) and human JAK2 V617F (hJAK2) mutations. B41, band 4.1 domain; SH2, 
src-homology domain; JH2, pseudokinase domain; JH1, kinase domain. (B) Mouse APL Jak1 V657F mutation allele frequency by 454 
sequencing. The variant allele frequencies of the V657F mutation from tumor 9500 and the 6 other tumors with V657F mutations are 
shown. On the far right are the read counts for the controls of a WT 129/SvJ DNA pool (n = 6) and a WT B6/T DNA pool (n = 6). F, 
female; M, male. (C) Functional validation with human JAK1 cDNA MSCV retroviral constructs. IRES-GFP (WT/GFP) alone versus JAK1 
WT-IRES-GFP (WT/JAK1 WT) versus JAK1 V658F (WT/JAK1 V658F) mutant-IRES-GFP retroviral constructs were transduced into WT 
B6/T or mCG-PR bone marrow from 6-week-old mice. The transduced marrow was transplanted into lethally irradiated WT B6/T mice. 
The JAK1 V658F mutant cooperates with PML-RARA (PR) in a mouse model of APL and causes a fatal leukemia; a Kaplan-Meier overall 
survival plot is shown. This result was replicated in 2 independent experiments. (D) Serial flow cytometric analysis of peripheral blood 
shows a massive expansion of GFP+/Gr-1+ cells in the mCG-PR/JAK1 V658F cohort compared with that in the other experimental cohorts 
and controls. Error bars are mean ± SEM. (E) Flow cytometric analysis of peripheral blood, bone marrow, and spleen at the end of 1 JAK1 
functional validation experiment showed no significant expansion of GFP+/Gr-1+ cells in cohorts other than mCG-PR/JAK1 V658F mice. 
Each symbol represents an individual mouse. Error bars are mean ± SEM.
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Structural variant analysis of the sequenced mouse APL genome, with discovery and validation of a somatic 150-kb deletion on chromosome X 
that included nearly all of the Kdm6a gene also somatically deleted in 1 human AML sample. (A) Copy number depth plot by sequence coverage 
for the tumor 9500 and 129/SvJ genomes in the same region on chromosome X that includes exons 3–29 of the Kdm6a locus. The 129/SvJ 
strain has no deletion in this region. (B) PCR validation of the tumor 9500 deletion. The PCR product was cloned and sequenced to confirm the 
breakpoints of the deletion. (C) High-resolution copy number depth plot of a human AML sample with a KDM6A deletion (exons 1–3 are deleted). 
The copy number plot compares the tumor to skin DNA array data from the same patient using the Affymetrix v6.0 SNP array platform. (A and 
C) The green lines represent the average copy number for the affected intervals, and the black lines represent the average copy number for the 
unaffected regions. Red dots represent individual copy number data points within the affected intervals, and blue dots represent individual copy 
number data points for the unaffected regions.
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Functional validation of a recurrent Jak1 mutation identified in the 





































Heat map of Kdm6a deletions in 4 
mouse APL tumors based on targeted 
NimbleGen custom 12 × 135 K CGH 
array data. Kdm6a deletions are not 
residual germline CNVs (there are 2 
copies of this region in the 129/SvJ 
strain). Deletions of Kdm6a in the 4 
tumors have unique breakpoints and 
are not consistent with a founder 
effect or strain variant. On the right 
side of the heat map, B6 and 129 
represent the B6 and 129/SvJ WT 
samples, respectively, that were 
used as controls, and 9500, 9520, 26, 
and 9495 represent individual mouse 
tumor numbers.
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Schematic representation of the 4 Kdm6a deletions found in mouse APL tumors (tumors 9500, 9520, 26, and 9495) and a KDM6A deletion 
found in a human AML patient (sample 750152). Mouse APL tumor 26 has 2 deletions involving Kdm6a, a 41.4-kb deletion and a smaller 8-kb 
deletion. Chr X, chromosome X.
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Kdm6a deletions in APL tumors
Tumor	 Deletion	start	(bp)	 Deletion	end	(bp)	 Deletion	size	(bp)	 Exons	affected
Mouse 9500 17,753,180 17,904,432 151,252 Kdm6a 3–29
Mouse 9520 ~17,714,248 ~17,781,365 ~67,117 Dusp21 1, Kdm6a 1–3
Mouse 26 ~17,714,999 ~17,756,399 ~41,400 Dusp21 1, Kdm6a 1 and 2
Mouse 26 ~17,782,706 ~17,790,700 ~7,994 Kdm6a 4
Mouse 9495 ~17,715,436 ~17,749,804 ~34,368 Dusp21 1, Kdm6a 1 and 2
Human 750152 44,433,508 44,716,476 282,968 DUSP21 1, KDM6A 1–3
The table includes the deletion breakpoints, deletion size, and exons of genes affected for the 4 deletions involving Kdm6a found in mouse APL tumors and 
corresponds to the schematic representation shown in Figure 6.
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Functional validation using the transduction-transplantation mouse model with 
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